A Look Ahead to the 2019 SABCS Meeting
  • CME

December 10-14, 2019; San Antonio, Texas
Experts highlight key data to help you prepare for what to expect at the upcoming breast cancer meeting in San Antonio. The CCO Conference Coverage program will feature downloadable slides and expert commentaries of clinically relevant studies presented at SABCS 2019. We will have the information you need to understand and integrate the latest data on optimizing breast cancer care into your practice.
Sara Hurvitz, MD, FACP
Joyce O'Shaughnessy, MD
Sara Tolaney, MD, MPH
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Released: December 9, 2019 Expiration: December 8, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with breast cancer
  • Discuss new data on novel agents and therapeutic approaches for patients with early-stage and metastatic breast cancer
  • Consider how new trial findings might affect treatment of breast cancer clinical practice in the future
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Daiichi Sankyo, Inc.
Genentech
Merck Sharp & Dohme Corp
Puma Biotechnology
Seattle Genetics

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Sara Hurvitz, MD, FACP

Associate Professor of Medicine
Director,
Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara Hurvitz, MD, FACP, has disclosed that she has received funds for research support from Ambrx, Bayer, Daiichi-Sankyo, Dignitana, Genentech/Roche, GlaxoSmithKline, Immunomedics, Lilly, MacroGenics, Novartis, OBI Pharma, Pfizer, Pieris, Puma, Radius, Sanofi, and Seattle Genetics and consulting fees from Pfizer and Roche
Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Director,
Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas

Joyce O’Shaughnessy, MD, has disclosed that she has received consulting fees from AbbVie, Agendia, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron, Ipsen, Jounce, Lilly, Merck, Myriad, Novartis, Odonate, Pfizer, Puma, Roche, Seattle Genetics, and Syndax
Sara Tolaney, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women's Cancer
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Senior Physician

Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Sara Tolaney, MD, MPH, has disclosed that she has received funds for research support paid to her institution from AstraZeneca, Bristol-Myers Squibb, Cyclacel, Exelixis, Eisai, Genentech/Roche, Immunomedics, Lilly, Merck, Nektar, Novartis, Odonate, Pfizer, and Sanofi and consulting fees from AbbVie, AstraZeneca, Athenex, Bristol-Myers Squibb, Celldex, Daiichi-Sankyo, Eisai, Genentech, Immunomedics, Lilly, Merck, NanoString, Nektar, Novartis, Paxman, Pfizer, Puma, Sanofi, and Seattle Genetics.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Rachael M. Andrie, PhD

Scientific Director

Rachael Andrie, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with breast cancer.

Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with breast cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 09, 2019, through December 08, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Sara Tolaney, MD, MPH, provides insights on key studies on the treatment of HER2-negative and triple-negative breast cancer from 2019 SABCS for Clinical Care Options (CCO)

Sara Tolaney, MD, MPH Released: January 27, 2020

CME-certified Webcast of a CCO symposium at SABCS 2019 featuring expert perspectives on evolving strategies for treating HR-positive, HER2-negative advanced breast cancer

Joyce O'Shaughnessy, MD
Program Director
Hope S. Rugo, MD Eric P. Winer, MD
Physicians: maximum of 1.75 AMA PRA Category 1 Credits US Physicians: maximum of 1.75 Medical Knowledge MOC point(s) Released: January 21, 2020 Expiration: January 20, 2021

CCO faculty Dr. Heather McArthur provides insights on trastuzumab deruxtecan and tucatinib for patients with HER2+ MBC who have progressed on standard-of-care HER2-targeted therapies

Heather McArthur, MD, MPH Released: January 21, 2020

CCO faculty Sara Hurvitz, MD, FACP, provides her thoughts on key studies in HER2+ breast cancer presented at the 2019 Breast Cancer meeting in San Antonio

Sara Hurvitz, MD, FACP Released: January 13, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?